Marked Choroidal Thinning Observed after Intravitreal Brolucizumab Injection

Introduction: Here, we report a case of severe intraocular inflammation (IOI) and prominent choroidal thinning following the initial intravitreal brolucizumab injection (IVBr). Case Presentation: The patient was a 75-year-old Japanese man with type 2 age-related macular degeneration of both eyes. Un...

Full description

Bibliographic Details
Published in:	Case Reports in Ophthalmology
Main Authors:	Yoshiki Ueta, Ryoma Kamada, Yuji Watanabe, Nobuya Tanaka
Format:	Article
Language:	English
Published:	Karger Publishers 2023-11-01
Subjects:	case report brolucizumab intravitreal injection intraocular inflammation choroidal thinning
Online Access:	https://beta.karger.com/Article/FullText/534817

Similar Items

A case of choroidal neovascular membrane in Best vitelliform macular dystrophy treated with intravitreal brolucizumab
by: Pradeep K Panigrahi, et al.
Published: (2023-04-01)

Efficacy of Intravitreal Brolucizumab Switch in Pachychoroid Neovasculopathy
by: Nicolò Ribarich, et al.
Published: (2025-07-01)

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result
by: Wataru Kikushima, et al.
Published: (2023-04-01)

Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
by: Yoshiko Fukuda, et al.
Published: (2021-09-01)

Scleritis following intravitreal brolucizumab injection: a case series
by: Takuya Takayama, et al.
Published: (2024-02-01)

Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab
by: Settimio Rossi, et al.
Published: (2025-01-01)

Efficacy and safety of treat-and-extend intravitreal brolucizumab in naive and switched patients with macular neovascularization: one-year follow-up study
by: Francesco Faraldi, et al.
Published: (2024-10-01)

Discrepancies in choroidal thickness and brolucizumab intravitreal injection: Cause or effect of intraocular inflammation?
by: Sunny, Chi Lik Au
Published: (2024-10-01)

Delayed noninfectious intraocular inflammation and retinal vasculitis after single intravitreal Brolucizumab® injection for polypoidal choroidal vasculopathy
by: Ramesh Venkatesh, et al.
Published: (2024-01-01)

Indocyanine green angiographic documentation of regression of polypoidal lesions after brolucizumab injection in polypoidal choroidal vasculopathy
by: Kedarisetti Kiran Chandra, et al.
Published: (2023-07-01)

Hyperreflective foci (HRFs): A novel biomarker for intraocular inflammation (IOI) following intravitreal Brolucizumab
by: Vasumathy Vedantham, et al.
Published: (2023-10-01)

Brolucizumab in patients with neovascular age-related macular degeneration: Real-life outcomes from a tertiary care eye hospital
by: Lorenzo Fabozzi, et al.
Published: (2024-11-01)

Efficacy of reduced dose of intravitreal triamcinolone acetonide in a case of active serpiginous choroiditis
by: Avirupa Ghose, et al.
Published: (2016-01-01)

Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration
by: Mehta N, et al.
Published: (2023-02-01)

Changes in Aqueous Humor Cytokine Profile Following Intravitreal Brolucizumab Injection
by: Ruamviboonsuk V, et al.
Published: (2025-02-01)

Multiple Intravitreal Ranibizumab Injections for Persistant Choroidal Neovascularization Associated with Presumed Ocular Histoplasmosis Syndrome
by: Turgut Yılmaz, et al.
Published: (2017-03-01)

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration
by: Alaa Din Abdin, et al.
Published: (2022-05-01)

Short-Term Comparison of Switching to Brolucizumab or Faricimab from Aflibercept in Neovascular AMD Patients
by: Akiko Kin, et al.
Published: (2024-07-01)

The Real-World Results of the Single Intravitreal Injection of Faricimab in Treatment-Naïve Subfoveal Myopic Choroidal Neovascularization
by: Hao-Chun Chang, et al.
Published: (2026-04-01)

Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study
by: Debdulal Chakraborty, et al.
Published: (2023-01-01)

Early OCTA Changes of Type 3 Macular Neovascularization Following Brolucizumab Intravitreal Injections
by: Anthony Gigon, et al.
Published: (2022-08-01)

Intravitreal topotecan inhibits laser-induced choroidal neovascularization in a rat model
by: Mohammad Ali Gholipour, et al.
Published: (2015-01-01)

Brolucizumab Intravitreal Injections for Wet Age-Related Macular Degeneration: Real-Life Study on a Cohort of Italian Patients
by: Carlo Gesualdo, et al.
Published: (2023-06-01)

Proactive Post-Injection Monitoring in Brolucizumab Therapy: A Study on Intraocular Inflammation and Treatment Outcomes
by: Soman M, et al.
Published: (2025-04-01)

Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration
by: Sara J. Haug, et al.
Published: (2020-06-01)

Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group
by: Manisha Agarwal, et al.
Published: (2024-07-01)

Retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab injections for diabetic macular edema
by: Takao Hirano, et al.
Published: (2023-03-01)

Intravitreal injections in the context of incarcerated patients
by: Jędrzej Dzięgielewski, et al.
Published: (2023-11-01)

subfoveal choroidal thickness before and after intravitreal Ranibizumab injection in patients with choroidal neovascularization
by: Mahmoud Elabiad, et al.
Published: (2023-01-01)

Comparative Study on Anti-VEGF in Wet Age-Related Macular Degeneration in the Setting Based on Lean Methodology from the Bari Intravitreal Injection Registry (BIVIR)
by: Maria Oliva Grassi, et al.
Published: (2024-04-01)

Incidence of intraocular inflammation and its risk factors in patients treated with brolucizumab: a nationwide cohort study
by: Hyo Song Park, et al.
Published: (2024-10-01)

Real-world experience of brolucizumab in nAMD
by: Shilpi H Narnaware, et al.
Published: (2024-01-01)

Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment
by: Natsuki Ueji, et al.
Published: (2023-10-01)

The Short-Term Effect of Intravitreal Bevacizumab Injection on Intraocular Pressure
by: Şehnaz Özçalışkan, et al.
Published: (2014-10-01)

The Short-term efficacy of a monoclonal antibody fragment (brolucizumab) for treating neovascular age-related macular degeneration
by: A. F. Yusupov, et al.
Published: (2024-07-01)

Adjuvant Intravitreal Bevacizumab Injection for Choroidal and Orbital Metastases of Refractory Invasive Ductal Carcinoma of the Breast
by: I-Hung Lin, et al.
Published: (2021-04-01)

Evaluating photodynamic therapy versus brolucizumab as a second-line treatment for polypoidal choroidal vasculopathy
by: Ryoh Funatsu, et al.
Published: (2024-04-01)

One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy
by: Hsin-Yu Weng, et al.
Published: (2019-05-01)

Indirect choroidal neovascularization secondary to a posterior-segment intraocular foreign body – case report
by: Yu-Hsiuan Lin, et al.
Published: (2020-04-01)

Long-term analysis of intravitreal brolucizumab in recalcitrant cases of chronic central serous retinopathy complicated by neovascularization (pachychoroid neovasculopathy)
by: Lalit Verma, et al.
Published: (2026-06-01)